New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2012
10:20 EDTEA, SYNC, NCMI, TNB, SIGA, MAKO, SNCR, RHHBY, EP, BP, ERJ, ACMOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AECOM Technology (ACM) downgraded to Underperform from Buy at BofA/Merrill... BP (BP) downgraded to Underweight from Equal Weight at Barclays... El Paso (EP) downgraded to Underweight from Neutral at Atlantic Equities... Embraer (ERJ) downgraded to Neutral from Buy at Citigroup... Mako Surgical (MAKO) downgraded to Neutral from Buy at Mizuho... National CineMedia (NCMI) downgraded to In-Line from Outperform at Imperial Capital... Roche (RHHBY) downgraded to Neutral from Overweight at JPMorgan... SIGA Technologies (SIGA) downgraded to Sector Perform from Outperform at RBC Capital... Synacor (SYNC) downgraded to Underperform from Buy at BofA/Merrill... Synchronoss (SNCR) downgraded to Market Perform from Outperform at Wells Fargo... Thomas & Betts (TNB) downgraded to Neutral from Outperform at RW Baird... Electronic Arts (EA) downgraded to Market Perform from Outperform at William Blair.
News For ACM;BP;EP;ERJ;MAKO;NCMI;RHHBY;SIGA;SYNC;SNCR;TNB;EA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 15, 2015
06:44 EDTBPEnvironmentalists file lawsuit over oil train safety rules, NY Times says
Subscribe for More Information
05:52 EDTEAApril NPD video game software sales rose 13%, says Piper Jaffray
Piper Jaffray notes April NPD video game software sales increased 13% year-over-year with next-generation software revenue up 200% versus the prior year. Piper keeps Overweight ratings on Activision Blizzard (ATVI), Electronic Arts (EA), GameStop (GME) and Take-Two (TTWO).
May 14, 2015
09:22 EDTRHHBYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
May 13, 2015
18:12 EDTRHHBYGenentech alectinib shrank tumors in about half of ALK-positive NSCLC patients
Subscribe for More Information
17:04 EDTRHHBYGenentech announces interim results from POPLAR study
Genentech, a member of the Roche Group announced interim results from a global, randomized Phase II study, POPLAR, in people with previously treated non-small cell lung cancer, NSCLC. The study showed the investigational cancer immunotherapy MPDL3280A doubled the likelihood of survival; hazard ratio [HR]=0.47) in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy. An improvement in survival was also observed in people who had medium and high or any level of PD-L1 expression, as characterized by a test being developed by Roche. MPDL3280A was generally well tolerated and adverse events were consistent with what has been previously reported for MPDL3280A in NSCLC. Updated results will be presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology. “In our study of MPDL3280A in previously treated lung cancer, the amount of PD-L1 expressed by a person’s cancer correlated with improvement in survival,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “The goal of PD-L1 as a biomarker is to identify people most likely to experience improved overall survival with MPDL3280A alone, and which people may be appropriate candidates for a combination of medicines.”
11:08 EDTACMOptions with decreasing implied volatility
Subscribe for More Information
May 12, 2015
10:01 EDTNCMIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:51 EDTNCMINational CineMedia management to meet with FBR Capital
Meeting to be held in New York on May 13 hosted by FBR Capital.
07:04 EDTACMAECOM raises FY15 adjusted EPS view to $3.15-$3.55 from $2.75-$3.35
Subscribe for More Information
07:03 EDTACMAECOM reports Q2 adjusted EPS 58c, consensus 53c
Subscribe for More Information
06:57 EDTNCMINational CineMedia upgraded to Outperform from Market Perform at FBR Capital
Subscribe for More Information
05:38 EDTBPTechnip awarded lump sum project by BP Exploration & Production
Subscribe for More Information
May 11, 2015
16:08 EDTNCMINational CineMedia backs FY15 revenue view $422M-$432M, consensus $423.67M
Subscribe for More Information
16:07 EDTNCMINational CineMedia sees Q2 revenue $116M-$122M, consensus $111.48M
Q2 Adjusted OIBDA is expected to be up 17%-29% from the second quarter of 2014, or $61M-$67M.
16:05 EDTNCMINational CineMedia reports Q1 adjusted EPS 1c, consensus (5c)
Subscribe for More Information
15:00 EDTACMNotable companies reporting before tomorrow's open
Subscribe for More Information
15:00 EDTNCMINotable companies reporting after market close
Subscribe for More Information
13:28 EDTBPOPEC sees oil at around $76 a barrel in 2025, WSJ says
Subscribe for More Information
10:29 EDTEAElectronic Arts management to meet with Jefferies
Subscribe for More Information
05:11 EDTRHHBYRoche receives FDA approval for cobas KRAS Mutation Test
Roche announced that the FDA has approved the cobas KRAS Mutation Test for diagnostic use. The real-time PCR test is designed to identify KRAS mutations in tumor samples from metastatic colorectal cancer, or mCRC, patients and aid clinicians in determining a therapeutic path for them.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use